Document is current
Any future updates will be listed below
-
Authors
O’Keeffe, Piper
Nouri, Yasmin
Saw, Hui Shi
Moore, Zachery
Baldwin, Tracey M.
Olechnowicz, Sam W. Z.
Jabbari, Jafar S.
Squire, David McG
Leslie, Stephen
Wang, Changqing
You, Yupei
Ritchie, Matthew E.
Cross, Ryan S.
Jenkins, Misty R.
Audiger, Cindy
Naik, Shalin H.
Whittle, James R.
Freytag, Saskia
Best, Sarah A.
Hickey, Peter F.
Amann-Zalcenstein, Daniela
Bowden, Rory
Brown, Daniel V.
-
Funding
Funding for this research was provided by:
Malaghan Institute Fellowship
Greg Lange Fellowship
NHMRC Investigator Grant (APP2032982)
Carrie’s Beanies 4 Brain Cancer
VCA mid-career research fellowship (MCRF22003)
WEHI New Medicines and Advanced Technologies theme
- License Information
-
More Information
Article History
Received: 21 November 2024
Accepted: 10 April 2025
First Online: 2 May 2025
Declarations
:
: JRW reports research funding from AnHeart Therapeutics; received consulting fees from AnHeart Therapeutics and Servier; being on advisory boards for Roche and Merck; is a data safety monitoring member for Telix Pharmaceuticals. The remaining authors declare no conflict of interest.
: PBMCs were isolated from unrelated healthy control donor samples from the Australian Red Cross lifeblood donor Registry (23-06VIC-16).Informed consent was obtained from all individual participants prior to inclusion in the study. The study was performed according to the principles of the 1964 Helsinki declaration and its later amendments and was approved by local Human Research Ethics Committee (17-01LR) and project 21/21.Mice (C57BL/6) were sourced from the Clive and Vera Ramaciotti Laboratory (WEHI) and bred and maintained under specific pathogen-free conditions. Experiments were performed in accordance with institutional guidelines (WEHI Animal Ethics Committee 2021.051 and 2021.054). This study was conducted in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.
